Enoxaparin API Market - Global Industry Analysis 2015 - 2019 and Opportunity Assessment; 2020 - 2030


Enoxaparin Api  Market
  • To Be Published : Jan-2021 |
  • Status : Work in progress |
  • Format : Enoxaparin Api  Market Enoxaparin Api  Market Enoxaparin Api  Market Enoxaparin Api  Market

Enoxaparin is made from heparin and is one type of the low molecular weight heparin (LMWH). It is used as an anticoagulant that prevents the formation of blood clots also known as ‘blood thinner’. It is used to treat various conditions including deep vein thrombosis (DVT), pulmonary embolism in the lungs, acute coronary syndrome and heart attack. An incidence rate of venous thromboembolism was observed around ~0.1% to 0.2% in the U. S. population. As per WHO classification, enoxaparin has listed under essential medicines and was considered as the most commonly prescribed medication in the U. S.

In the COVID-19 pandemic, millions of the individual has been affected globally by COVID-19 infection. In significant severe cases, blood density/clot was one of the major observed complication.  The national healthcare authorities has rendered advice to all medical and public healthcare faciltiies regarding the need of enoxaparin availability. The COVID-19 outbreak is expected to feul the growth of enoxaparin API market.

The rise in unmet global demand of the blood thinner drugs is expected to drvie the  enoxaparin API market globally owing to increase in the prevalence of chronic and cardiovascular diseases. Availability of low molecular weight enoxaparin (LMWH) over unfractionated heparin is one of the major factor that is expected to propel the market growth over the forecast period. The rise in the price of enoxaparin API in China has a significant negative impact on the growth of market. Adverse effects associated with enoxaparin during treatment is expcted to hamper the growth of the enoxaparin API market. Strigent regulatory norms in the developed markets is expected to contract the growth of the enoxaparin API market.

Globally, the enoxaparin API market is segmented based on dose strength, packaging, application, end user, and region.

Based on molecular weight, the enoxaparin API market is segmented as:

  • High Molecular Weight
  • Low Molecular Weight

Based on packaging, the enoxaparin API market is segmented as:

  • Multi Vials
  • Pre-filled Syringes

Based on indication, the enoxaparin API market is segmented as:

  • Deep Vein Thrombosis
  • COVID-19
  • Acute Coronary Syndrome
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Others

Based on end user, the enoxaparin API market is segmented as:

  • Pharmaceutical Manufacturers
  • Contract Manufacturing Organizations
  • Research and Development Organization

Based on the region, the enoxaparin API market is segmented as:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle-East & Africa (MEA)

High molecular weight of enoxaparin hold the major revenue share in the global enoxaparin API market. By packaging, multi vials segment leads the market share in the global enoxaparin API market. Multi vials packaing provide low cost alternative to a huge demand of the enoxaparin treatment. Pulmonary embolism dominate the global enoxaparin API market by the indication owing to high incidecne of the pulmonary embolism across the globe. COVID-19 is becoming a dominant disruptive factor in the global market as it has significantly surged the demand of the blood thinners across the world. Pharmaceutical manufacturers end user hold the major revenue share followed by the contract manufacturing organization in the global enoxaparin API market.

Asia Pacific is dominating the market and is expected to increase over the next few years due to well-estblished state-of-art facilties in the region. North America and Europe is expected to second most opportunitstic market in the Enoxaparin API market owing to rise in the pharmcautical manufacturers in the region. Latin America is emerging and may expect to grow moderately in the future. Usage of enoxaparin in China is increasing in 2019 and is expected to increase more till 2025 that will propel the growth of market.

The key players operating in the enoxaparin API market are Shenzhen Hepalink Pharmaceutical Group, Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Bristol Myer Squibb Company, Bohehringer Ingelheim, Eisai Inc., Teva Pharmaceutical Industries Ltd., Abbot India Limited, Novartis AG, ChemWerth, Laboratorios Farmaceuticos ROVI SA, Gland Pharma Limited, Hanways Chempharma Co. Ltd, Changzhou Qianhong Biopharma, and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, dosage strength, packaging, indication, and end users.

The report on the Enoxaparin API market covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2015 - 2019
  • Market Size & Forecast 2020 to 2030
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
  • Market Drivers and Restraints

Regional analysis for Enoxaparin API market includes

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

 Report on Enoxaparin API market highlights:

  • Shifting industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance
Back To Top